<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations, evaluation, and diagnosis of interstitial lung disease in systemic sclerosis (scleroderma)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations, evaluation, and diagnosis of interstitial lung disease in systemic sclerosis (scleroderma)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations, evaluation, and diagnosis of interstitial lung disease in systemic sclerosis (scleroderma)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John Varga, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Talmadge E King, Jr, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John S Axford, DSc, MD, FRCP, FRCPCH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 12, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Interstitial lung disease (ILD) is one of the major forms of lung involvement in patients with systemic sclerosis (SSc). SSc-associated ILD consists of various histopathologic subtypes, most commonly nonspecific interstitial pneumonitis and usual interstitial pneumonitis. Affected patients have a worse prognosis than patients with SSc who are free of pulmonary involvement.
        </p>
        <p>
         The clinical manifestations, evaluation, and diagnosis of SSc-associated ILD are discussed here. The treatment of SSc-associated ILD, the evaluation and management of pulmonary arterial hypertension and other pulmonary complications of SSc are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4377.html" rel="external">
          "Overview of pulmonary complications of systemic sclerosis (scleroderma)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">
          "Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8251.html" rel="external">
          "Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Definition, risk factors, and screening"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The reported prevalence of ILD in patients with SSc varies based upon population studied and definition of ILD [
         <a href="#rid1">
          1-4
         </a>
         ]. In one study of 779 patients with SSc, 48 percent of those with diffuse cutaneous SSc and 26 percent of those with limited cutaneous SSc were found on HRCT to have ILD [
         <a href="#rid1">
          1
         </a>
         ]. In separate studies that identified ILD by HRCT, the prevalence of ILD in SSc was 50 to 60 percent [
         <a href="#rid5">
          5,6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4041211263">
         <span class="h1">
          RISK FACTORS FOR ILD
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diffuse cutaneous SSc, which is characterized by extensive skin involvement and extension of skin sclerosis proximal to the elbows, is a risk factor for developing ILD early in the course of SSc [
         <a href="#rid7">
          7,8
         </a>
         ]. Patients with limited cutaneous SSc, in which skin sclerosis is generally restricted to the hands, distal extremities, and, to a lesser extent, the face and neck, are less likely to develop ILD early in the course of disease, but may develop ILD as a late manifestation [
         <a href="#rid7">
          7,9,10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4377.html" rel="external">
          "Overview of pulmonary complications of systemic sclerosis (scleroderma)", section on 'Influence of diffuse cutaneous and limited cutaneous disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">
          "Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Background'
         </a>
         .)
        </p>
        <p>
         Other features that may predict early development of ILD in patients with SSc include African-American ethnicity, higher skin score and serum creatine phosphokinase (CPK) levels, hypothyroidism, and cardiac involvement [
         <a href="#rid2">
          2,11
         </a>
         ]. Anticentromere antibodies appear protective against ILD, whereas the presence of anti-topoisomerase I (antiScl-70) antibodies increases the likelihood of ILD [
         <a href="#rid2">
          2,3,8,10,12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Early ILD is frequently asymptomatic. The most common symptoms of SSc-associated ILD are fatigue, breathlessness (ie, exertional dyspnea initially), and dry cough. Chest pain is infrequent, and hemoptysis is rare.
        </p>
        <p>
         While most patients have cutaneous manifestations of SSc at the time ILD is identified, occasional patients present first with ILD and are subsequently found to have SSc based on the presence of findings such as Raynaud phenomenon, sclerodactyly, positive autoantibodies (eg, antinuclear antibody, antitopoisomerase [anti-Scl70]), or abnormal nailfold capillary microscopy  (
         <a class="graphic graphic_figure graphicRef94667" href="/z/d/graphic/94667.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7543.html" rel="external">
          "Clinical manifestations and diagnosis of Raynaud phenomenon", section on 'Nailfold capillary microscopy'
         </a>
         .)
        </p>
        <p>
         The most characteristic finding of ILD on physical examination is bibasilar fine inspiratory crackles (ie, "Velcro" rales) at the lung bases [
         <a href="#rid13">
          13
         </a>
         ]. Finger clubbing is uncommon. Signs of cor pulmonale can be seen with advanced ILD, but are more commonly associated with pulmonary hypertension, which may occur in SSc as a separate process or in association with ILD.
        </p>
        <p class="headingAnchor" id="H94894947">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         SSc-associated ILD is usually suspected when a patient with known SSc develops exertional dyspnea, cough, auscultatory crackles, or abnormalities on pulmonary function testing (PFTs) or the chest radiograph. The evaluation of suspected ILD in a patient with SSc is similar to that of other patients with suspected ILD. However, a lung biopsy is almost never required to secure a diagnosis of SSc-ILD. A general diagnostic approach to the patient with ILD is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4310.html" rel="external">
          "Approach to the adult with interstitial lung disease: Clinical evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing"
         </a>
         .)
        </p>
        <p>
         Investigations evaluating suspected SSc-associated ILD are designed to characterize the type and severity of ILD and to exclude the possibility that another lung disease or extra-pulmonary process is etiologic, such as infection, heart failure, drug-induced lung disease, or recurrent aspiration.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Laboratory findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of characteristic autoantibodies supports the diagnosis of systemic sclerosis and may indicate an increased likelihood of specific clinical manifestations, such as ILD, but none are diagnostic of ILD. As an example, anti-topoisomerase I (also known as anti-Scl-70) antibody, which is typically determined as part of the diagnostic evaluation of patients with suspected SSc, is associated with an increased risk for SSc-associated ILD (sensitivity 45 percent, specificity 81 percent) [
         <a href="#rid14">
          14
         </a>
         ]. The role and availability of specific laboratory tests in the diagnosis and management of SSc is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">
          "Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Laboratory testing'
         </a>
         .)
        </p>
        <p>
         Additional SSc-related autoantibodies have also been associated with an increased risk for ILD, including anti-U3 ribonucleoprotein (RNP), anti-U11/U12 RNP, and anti-Th/To [
         <a href="#rid15">
          15-21
         </a>
         ]. However, these tests might not be commercially available, and their clinical utility in the evaluation and management of SSc-associated ILD is currently still uncertain.
        </p>
        <p>
         Anticentromere antibodies (ACA), which are common among patients with limited cutaneous SSc and can be associated with pulmonary arterial hypertension, are rarely associated with significant ILD [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Pulmonary function testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         PFTs are performed in patients with SSc at the time of initial diagnosis to determine the presence and extent of SSc-associated lung involvement. Subsequently, PFTs are generally performed annually or more frequently to evaluate new onset of dyspnea, cough, or radiographic abnormality. The pattern of abnormalities on PFTs can help to differentiate among the various types of SSc lung involvement. (See
         <a class="medical medical_review" href="/z/d/html/4377.html" rel="external">
          "Overview of pulmonary complications of systemic sclerosis (scleroderma)", section on 'Types of pulmonary involvement'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Spirometry – A proportional reduction of the forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ) and forced vital capacity (FVC; ie, a normal FEV
         <sub>
          1
         </sub>
         /FVC ratio) suggests a restrictive defect and may be present in patients with ILD. However, early ILD in SSc patients cannot be excluded by normal spirometry. One study found that 62 percent of SSc patients with normal FVC had clinically important ILD identified by HRCT (false negative rate) [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4377.html" rel="external">
          "Overview of pulmonary complications of systemic sclerosis (scleroderma)", section on 'Pulmonary function testing'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">
          "Overview of pulmonary function testing in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lung volumes – The FVC, total lung capacity (TLC), functional residual capacity (FRC), and residual volume (RV) may be decreased in ILD. Patients with SSc who have a near-normal FVC at initial presentation have low risk for progression to severe ILD [
         <a href="#rid22">
          22
         </a>
         ]. However, normal lung volumes cannot be used to exclude early ILD [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">
          "Overview of pulmonary function testing in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diffusing capacity – The single breath diffusion capacity for carbon monoxide (DLCO) is a sensitive screening test for ILD, although rarely patients with SSc will have a normal DLCO despite radiographic evidence of ILD [
         <a href="#rid5">
          5,23
         </a>
         ]. A decrease in the DLCO may be the earliest PFT abnormality seen in patients with SSc-associated ILD but is nonspecific; other processes (eg, pulmonary hypertension, cigarette smoking, thromboembolic disease, as well as anemia) can also cause a decrease in DLCO. Among patients with SSc-associated ILD, the decrease in DLCO is usually proportionate to the decrease in lung volumes. Furthermore, the decrease in DLCO correlates with the severity of ILD detected by high-resolution computed tomography (HRCT) and is a predictor of poor outcome [
         <a href="#rid24">
          24,25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6972.html" rel="external">
          "Diffusing capacity for carbon monoxide"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Six-minute walk test – The six-minute walk test (6MWT) assesses both the distance walked (meters) and the degree of oxygen desaturation. It is used as a measure of submaximal exercise performance in a variety of pulmonary diseases (eg, idiopathic pulmonary fibrosis and pulmonary arterial hypertension). Assessment of pulse oxygen desaturation can be problematic in patients with SSc due to Raynaud phenomenon and poor finger perfusion. If the appropriate attachment is available, measurement of pulse oxygen saturation using an earlobe clip may be more reliable. Desaturation on ambulation is common to both ILD and pulmonary hypertension.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The value of the 6MWT is somewhat limited in SSc, as the distance walked does not discriminate well between patients with lung involvement and those without [
         <a href="#rid26">
          26
         </a>
         ]. This may be due to musculoskeletal and peripheral vascular complications.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Imaging
         </span>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Chest radiograph
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chest radiographs are relatively insensitive for the detection of early ILD and may be omitted if the patient has chest computed tomography instead. The classic radiographic features of established SSc-associated ILD consist of symmetric, reticular, or ground glass opacities. These are usually most pronounced at the lung bases.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          HRCT scanning
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with suspected SSc-ILD should undergo chest HRCT at initial evaluation. Imaging in both supine and prone positions is important because early radiologic changes of SSc-associated ILD are usually found in the dependent lung areas; scanning in the prone position is used to exclude the possibility of dependent atelectasis. (See
         <a class="medical medical_review" href="/z/d/html/6988.html" rel="external">
          "High resolution computed tomography of the lungs", section on 'Clinical application of HRCT'
         </a>
         .)
        </p>
        <p>
         The HRCT patterns found in SSc-associated ILD mirror the common histopathological patterns of the idiopathic interstitial pneumonias (eg, fibrotic nonspecific interstitial pneumonia [NSIP], usual interstitial pneumonia [UIP], and centrilobular fibrosis). (See
         <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">
          "Idiopathic interstitial pneumonias: Classification and pathology"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among patients with SSc-associated ILD, the most common pathologic pattern, NSIP, is associated with the HRCT finding of ground glass opacities in a peripheral distribution  (
         <a class="graphic graphic_diagnosticimage graphicRef70357" href="/z/d/graphic/70357.html" rel="external">
          image 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef72988" href="/z/d/graphic/72988.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid9">
          9,27,28
         </a>
         ]. The earliest HRCT change is usually a narrow, often ill-defined, subpleural crescent of increased density in the posterior (dependent) segments of the lower lobes. As the disease progresses, there is volume loss associated with a reticular appearance and traction bronchiectasis. The honeycomb pattern is rarely seen with NSIP.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the subset of patients with a histologic UIP pattern, the HRCT appearance is usually similar to that of fibrotic NSIP. However, sometimes the HRCT pattern is more consistent with that of UIP with bibasilar reticular opacities  (
         <a class="graphic graphic_diagnosticimage graphicRef98499" href="/z/d/graphic/98499.html" rel="external">
          image 2
         </a>
         ), associated with traction bronchiectasis and the development of subpleural honeycomb air spaces, which ultimately coalesce into large cystic air spaces  (
         <a class="graphic graphic_diagnosticimage graphicRef72569" href="/z/d/graphic/72569.html" rel="external">
          image 3
         </a>
         and
         <a class="graphic graphic_picture graphicRef74479" href="/z/d/graphic/74479.html" rel="external">
          picture 2
         </a>
         ) [
         <a href="#rid9">
          9,27,29,30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Centrilobular fibrosis is a rare pattern that is associated with patchy ground glass or consolidative opacities with a central distribution on HRCT scanning. In a series of 28 patients with SSc-associated ILD, six had centrilobular fibrosis on biopsy. In these patients, centrilobular fibrosis was associated with pathologic evidence of recurrent aspiration [
         <a href="#rid28">
          28
         </a>
         ]. Centrilobular nodules and “tree-in-bud” pattern are other features of recurrent aspiration. (See
         <a class="medical medical_review" href="/z/d/html/6988.html" rel="external">
          "High resolution computed tomography of the lungs", section on 'Centrilobular nodules'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The extent of ILD seen on HRCT is negatively correlated with FVC and is a powerful predictor of survival [
         <a href="#rid27">
          27,31,32
         </a>
         ]. In a prospective study of 215 patients with SSc, increasing extent of interstitial changes on HRCT was highly predictive of mortality [
         <a href="#rid31">
          31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">
          "Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22223262">
         <span class="h2">
          Bronchoalveolar lavage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bronchoscopy and bronchoalveolar lavage (BAL) in patients with SSc and suspected ILD are rarely indicated. Their main role is to exclude other causes of ILD. However, for SSc patients with atypical features, such as fever, productive cough, hemoptysis, peripheral blood eosinophilia, or focal consolidation on chest imaging, bronchoscopy with BAL may be indicated. (See
         <a class="medical medical_review" href="/z/d/html/4303.html" rel="external">
          "Basic principles and technique of bronchoalveolar lavage"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">
          "Role of bronchoalveolar lavage in diagnosis of interstitial lung disease"
         </a>
         .)
        </p>
        <p>
         Patients with SSc-associated ILD typically have elevated numbers of granulocytes in their BAL fluid, particularly neutrophils and eosinophils, and may sometimes have an increase in lymphocytes and mast cells [
         <a href="#rid33">
          33-35
         </a>
         ]. However, the clinical significance of these findings is controversial. (See
         <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">
          "Role of bronchoalveolar lavage in diagnosis of interstitial lung disease"
         </a>
         .)
        </p>
        <p>
         Some centers have used BAL in SSc-associated ILD to assess the degree of alveolitis and predict the response to immunosuppressive therapy [
         <a href="#rid27">
          27,36,37
         </a>
         ]. However, the results from a multicenter clinical trial argue against the routine use of BAL to identify active or progressive ILD (ie, alveolitis). In this trial of 158 patients with early SSc-associated ILD, there was no difference in the change in FVC after 12 months when patients with BAL-defined alveolitis were compared to patients who had a normal BAL [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Lung biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lung biopsy is seldom warranted in the evaluation of SSc-associated ILD. Biopsy may be indicated in patients with imaging findings that are atypical for SSc-associated lung disease or are suggestive of granulomatous disease, a malignant process, or pulmonary infection, particularly in patients receiving immunosuppressive drugs. When needed, a lung biopsy is typically obtained via video-assisted thoracoscopic surgery. Since SSc-associated ILD is predominantly subpleural, significant histologic changes are more likely to be found in peripheral lung biopsy than from tissue sampling of other locations [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">
          "Role of lung biopsy in the diagnosis of interstitial lung disease", section on 'Surgical lung biopsy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H89752766">
         <span class="h2">
          Pathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most frequently noted histopathologic finding on lung biopsy in SSc is fibrotic NSIP  (
         <a class="graphic graphic_picture graphicRef72988" href="/z/d/graphic/72988.html" rel="external">
          picture 1
         </a>
         )[
         <a href="#rid25">
          25,30,39-42
         </a>
         ]. Within the classification of NSIP, variable amounts of mononuclear cell infiltration and alveolar septal fibrosis can be seen. In SSc-associated NSIP, the pattern is more fibrotic and less inflammatory, thus leading to the designation fibrotic NSIP, rather than cellular NSIP. Additional characteristics of NSIP are temporal homogeneity and absence of fibroblast foci. (See
         <a class="medical medical_review" href="/z/d/html/4306.html" rel="external">
          "Treatment and prognosis of nonspecific interstitial pneumonia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">
          "Idiopathic interstitial pneumonias: Classification and pathology", section on 'Pathology'
         </a>
         .)
        </p>
        <p>
         In addition to the type of interstitial pneumonia, lung biopsy may reveal other histopathologic findings. In a series of lung biopsies from 34 patients with SSc, lymphocyte and plasma cell infiltration of the alveolar walls and interstitial fibrosis were noted, and approximately a fourth of the biopsies had focal lymphoid hyperplasia (also known as germinal centers or follicular bronchiolitis) [
         <a href="#rid43">
          43
         </a>
         ]. Intimal thickening of pulmonary arteries with resultant luminal narrowing is often found in postmortem lung specimens [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         A pattern consistent with UIP is occasionally seen in SSc [
         <a href="#rid9">
          9
         </a>
         ]. When compared with lung biopsies from patients with idiopathic pulmonary fibrosis, biopsies of SSc-associated UIP have a lower number of fibroblast foci and a higher number of germinal centers [
         <a href="#rid45">
          45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">
          "Idiopathic interstitial pneumonias: Classification and pathology", section on 'Pathology'
         </a>
         .)
        </p>
        <p>
         Rarely, histopathologic patterns consistent with other interstitial pneumonias are seen. In one series, four cases of respiratory bronchiolitis-associated interstitial lung disease were seen in patients who were cigarette smokers [
         <a href="#rid25">
          25
         </a>
         ]. Organizing pneumonia was seen in a patient taking
         <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">
          penicillamine
         </a>
         [
         <a href="#rid25">
          25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">
          "Idiopathic interstitial pneumonias: Classification and pathology", section on 'Pathology'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">
          "Idiopathic interstitial pneumonias: Classification and pathology", section on 'Cryptogenic organizing pneumonia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H94894994">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of SSc-associated ILD is generally based on the presence of the characteristic chest high-resolution computed tomography (HRCT) features of ILD in a patient with known SSc and exclusion of other etiologies of pulmonary parenchymal disease, such as heart failure, drug-induced lung toxicity, recurrent aspiration, or pulmonary vascular disease. (See
         <a class="local">
          'HRCT scanning'
         </a>
         above.)
        </p>
        <p>
         Once ILD is identified on HRCT, the radiographic pattern can generally be used to determine whether it is typical of the most common type of SSc-associated ILD, fibrotic nonspecific interstitial pneumonia, or another type of ILD, such as usual interstitial pneumonia. (See
         <a class="local">
          'Pathology'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H94895308">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of SSc-associated ILD includes ILD due to another rheumatic disease (eg, mixed connective tissue disease), ILD complicated by pulmonary arterial hypertension, heart failure, fluid overload, drug toxicity, recurrent aspiration, and rarely, pulmonary capillary hemangiomatosis or pulmonary veno-occlusive disease. Other types of ILD may need to be considered based on any history of exposures, such as medications, cigarette smoking (respiratory bronchiolitis-associated interstitial disease), silica, or organic dusts (hypersensitivity pneumonitis).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mixed connective tissue disease (MCTD) – MCTD is characterized by the presence of high titers of the autoantibody anti-U1 ribonucleoprotein (RNP, previously called antibody to extractable nuclear antigen) in a patient with overlapping features of systemic lupus erythematosus, SSc, and polymyositis. ILD occurs in about 50 to 66 percent of patients with MCTD. Differentiation of ILD due to SSc or MCTD is based on the pattern of other clinical manifestations and the presence of dominant autoantibodies to U1 RNP. The clinical manifestations and diagnosis of MCTD are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7546.html" rel="external">
          "Mixed connective tissue disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ILD with pulmonary hypertension (PH) – Among patients with SSc-associated ILD, some may have concomitant pulmonary arterial hypertension (PAH) that is indistinguishable from idiopathic PAH and others with advanced ILD can develop PH due to hypoxemia. Either of these processes can present with a reduction in diffusion capacity for carbon monoxide (DLCO) that appears greater than what would be expected based in the reduction in lung volume or high-resolution computed tomography (HRCT) abnormalities. Identification of PH contributor to dyspnea or a low DLCO is dependent on finding elevated pulmonary artery pressures on Doppler echocardiography followed by confirmation on right heart catheterization. (See
         <a class="medical medical_review" href="/z/d/html/8251.html" rel="external">
          "Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Definition, risk factors, and screening", section on 'Right heart catheterization'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Rare cases have been reported of patients with SSc who have pulmonary hypertension due to pulmonary capillary hemangiomatosis or veno-occlusive disease [
         <a href="#rid46">
          46-48
         </a>
         ]. The HRCT findings of pulmonary capillary hemangiomatosis (PCH) include a centrilobular pattern of ground-glass opacities, septal lines, pleural effusion, pericardial effusion, and/or mediastinal lymphadenopathy [
         <a href="#rid46">
          46
         </a>
         ]. The HRCT features of pulmonary veno-occlusive disease (PVOD) are similar with mediastinal lymph node involvement, centrilobular ground glass opacities, and septal thickening [
         <a href="#rid48">
          48
         </a>
         ]. It is important to distinguish these HRCT findings from SSc-associated ILD with PAH, as these patients are at increased risk for pulmonary edema associated with pulmonary vasodilator therapy. (See
         <a class="medical medical_review" href="/z/d/html/8269.html" rel="external">
          "Epidemiology, pathogenesis, clinical evaluation, and diagnosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heart failure and fluid overload – Heart failure can develop in SSc due to myocardial fibrosis which can lead to systolic or more often diastolic ventricular dysfunction. The diagnosis may be suspected on the basis of myositis, evidence of volume overload, or abnormal findings on transthoracic echocardiography. (See
         <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">
          "Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Evaluation for suspected systemic sclerosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug toxicity – Several drugs used to treat SSc are associated with drug-induced pulmonary disease, such as
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , and angiotensin converting enzyme inhibitors. Drug-induced lung toxicity should always be in the differential diagnosis of new respiratory signs, symptoms, and radiographic abnormalities. (See
         <a class="medical medical_review" href="/z/d/html/4349.html" rel="external">
          "Cyclophosphamide pulmonary toxicity"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4372.html" rel="external">
          "Methotrexate-induced lung injury"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4345.html" rel="external">
          "Pulmonary disease induced by cardiovascular drugs", section on 'Angiotensin-converting enzyme inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recurrent aspiration – Patients with SSc have a high rate of gastroesophageal reflux due to impaired esophageal peristalsis and, often, reduced tone of the lower esophageal sphincter  (
         <a class="graphic graphic_diagnosticimage graphicRef98499" href="/z/d/graphic/98499.html" rel="external">
          image 2
         </a>
         ). Thus, they are at increased risk for recurrent aspiration. Studies have found that presence of a dilated (patulous) esophagus on HRCT of the chest is associated with more severe radiographic ILD, lower lung volumes, and possibly greater progression of ILD [
         <a href="#rid49">
          49
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7548.html" rel="external">
          "Gastrointestinal manifestations of systemic sclerosis (scleroderma)", section on 'Esophageal involvement'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2245518212">
         <span class="h1">
          INVESTIGATIONAL TESTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several investigational biomarkers have shown a correlation with the presence of ILD in patients with SSc but are not clinically available [
         <a href="#rid11">
          11
         </a>
         ]. Krebs von den Lungen-6 (KL-6), a glycoprotein found predominantly on type II pneumocytes and alveolar macrophages, is elevated in the serum of patients with SSc-associated ILD and may correlate with the presence of pneumonitis and the radiological fibrosis score in patients with SSc [
         <a href="#rid50">
          50,51
         </a>
         ]. Serial measurements of serum KL-6 may eventually find a role in the diagnosis and monitoring of ILD in SSc [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         Similar prognostic roles have been proposed for surfactant proteins A and D, which also are elevated in the serum of most patients with SSc-associated lung disease [
         <a href="#rid52">
          52,53
         </a>
         ], and for CCL18, a chemokine that is abundantly expressed by pulmonary macrophages [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         Genetic factors might influence susceptibility to ILD in patients with SSc. As an example, one study found an association between SSc-associated ILD and the presence of human leukocyte antigen (HLA)-B*62 and HLA-Cw*0602, whereas PAH was associated with HLA-B*13 and HLA-B*65 [
         <a href="#rid55">
          55
         </a>
         ]. Other studies have demonstrated a strong association of SSc-associated ILD with variants of the interferon regulatory factor 5 (IRF5) gene [
         <a href="#rid56">
          56
         </a>
         ]. In contrast, genetic polymorphisms in MUC5B that are strongly associated with idiopathic pulmonary fibrosis do not appear to be a risk factor for SSc-associated ILD [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2787531103">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/118282.html" rel="external">
          "Society guideline links: Systemic sclerosis (scleroderma)"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/118793.html" rel="external">
          "Society guideline links: Interstitial lung disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and epidemiology
         </strong>
         – Interstitial lung disease (ILD) is one of the major forms of lung involvement in patients with systemic sclerosis (SSc). The prevalence of ILD approaches 50 percent of patients with diffuse cutaneous SSc (extensive skin involvement proximal to the wrists, particularly over the proximal limbs and trunk). (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4377.html" rel="external">
          "Overview of pulmonary complications of systemic sclerosis (scleroderma)", section on 'Types of pulmonary involvement'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – Early SSc-associated ILD may be asymptomatic. When symptoms develop, fatigue, breathlessness (ie, exertional dyspnea initially), and dry cough are most commonly reported. Chest pain is infrequent, and hemoptysis is rare. Bibasilar, fine inspiratory crackles (ie, "Velcro" rales) are the most characteristic finding of ILD; clubbing is uncommon. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – The evaluation of suspected ILD in a patient with SSc is similar to that of other patients with suspected ILD and is designed to characterize the type and severity of ILD and to exclude the possibility that another lung disease or extra-pulmonary process is etiologic. Most patients will require pulmonary function testing and high-resolution computed tomography (HRCT) of the chest. (See
         <a class="local">
          'Evaluation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4310.html" rel="external">
          "Approach to the adult with interstitial lung disease: Clinical evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pulmonary function testing
         </strong>
         – Reduced lung volumes and a reduced diffusing capacity for carbon monoxide (DLCO) are hallmarks of ILD and are usually proportionate in terms of changes from the percent predicted values. A decreased DLCO without a concomitant decrease in lung volumes is more typical of pulmonary arterial hypertension. (See
         <a class="local">
          'Pulmonary function testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Imaging
         </strong>
         – All patients with suspected SSc-ILD should undergo HRCT with supine and prone images. The typical HRCT finding is a peripheral, bibasilar distribution of ground glass opacities, consistent with nonspecific interstitial pneumonia (NSIP). With more advanced disease, reticular opacities increase and traction bronchiectasis becomes apparent, suggesting volume loss. The HRCT pattern in patients with the less common usual interstitial pneumonia (UIP) pattern is similar and may include honeycombing. Centrilobular fibrosis is a rare pattern that is associated with patchy ground glass or consolidative opacities with a central distribution on HRCT scanning. HRCT imaging in SSc might reveal the presence of ILD even in patients with no respiratory symptoms and normal PFTs (See
         <a class="local">
          'HRCT scanning'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Bronchoscopy with BAL, in select patients
         </strong>
         – Bronchoscopy with bronchoalveolar lavage (BAL) is rarely necessary in the evaluation of patients with suspected SSc-ILD. However, for patients with atypical features, such as fever, productive cough, hemoptysis, peripheral blood eosinophilia, or focal consolidation on chest imaging, bronchoscopy with BAL may be indicated. (See
         <a class="local">
          'Bronchoalveolar lavage'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of SSc-associated ILD is based on the presence of the characteristic chest HRCT features of ILD in a patient with known SSc and exclusion of other causes of ILD and does not usually require a lung biopsy. (See
         <a class="local">
          'Lung biopsy'
         </a>
         above and
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis of ILD in SSc includes ILD due to another rheumatic disease (eg, mixed connective tissue disease when the diagnosis of underlying SSc is not definitive), ILD in combination with pulmonary arterial hypertension, heart failure, drug toxicity, recurrent aspiration, and rarely, pulmonary capillary hemangiomatosis or pulmonary veno-occlusive disease. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           van Bon L, Affandi AJ, Broen J, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 2014; 370:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNearney TA, Reveille JD, Fischbach M, et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 2007; 57:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kane GC, Varga J, Conant EF, et al. Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status. Respir Med 1996; 90:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang B, Wigley FM, White B, Wise RA. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 2003; 30:2398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suliman YA, Dobrota R, Huscher D, et al. Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease. Arthritis Rheumatol 2015; 67:3256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steele R, Hudson M, Lo E, et al. Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res (Hoboken) 2012; 64:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilson M, Zerkak D, Wipff J, et al. Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases. Eur Respir J 2010; 35:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wangkaew S, Euathrongchit J, Wattanawittawas P, et al. Incidence and predictors of interstitial lung disease (ILD) in Thai patients with early systemic sclerosis: Inception cohort study. Mod Rheumatol 2016; 26:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischer A, Swigris JJ, Groshong SD, et al. Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest 2008; 134:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zanatta E, Huscher D, Ortolan A, et al. Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. Rheumatology (Oxford) 2022; 61:4786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khanna D, Tashkin DP, Denton CP, et al. Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease. Am J Respir Crit Care Med 2020; 201:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003; 5:80.
          </a>
         </li>
         <li class="breakAll">
          King TE Jr, Kim EJ, Kinder BW. Connective tissue diseases. In: Interstitial Lung Disease, 5th, Schwartz MI, King TE Jr. (Eds), People's Medical Publishing House, Shelton, CT 2011. p.689.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reveille JD, Solomon DH, American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003; 49:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steen VD, Powell DL, Medsger TA Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okano Y, Steen VD, Medsger TA Jr. Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 1993; 119:1005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sacks DG, Okano Y, Steen VD, et al. Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: Association with serum anti-U3RNP antibody. J Rheumatol 1996; 23:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace DJ, Lin HC, Shen GQ, Peter JB. Antibodies to histone (H2A-H2B)-DNA complexes in the absence of antibodies to double-stranded DNA or to (H2A-H2B) complexes are more sensitive and specific for scleroderma-related disorders than for lupus. Arthritis Rheum 1994; 37:1795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greidinger EL, Flaherty KT, White B, et al. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest 1998; 114:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005; 35:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fertig N, Domsic RT, Rodriguez-Reyna T, et al. Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum 2009; 61:958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plastiras SC, Karadimitrakis SP, Ziakas PD, et al. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 2006; 55:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Showalter K, Hoffmann A, Rouleau G, et al. Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis. J Rheumatol 2018; 45:1572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wells AU, Hansell DM, Rubens MB, et al. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum 1997; 40:1229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165:1581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garin MC, Highland KB, Silver RM, Strange C. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol 2009; 36:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldin JG, Lynch DA, Strollo DC, et al. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest 2008; 134:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Souza RB, Borges CT, Capelozzi VL, et al. Centrilobular fibrosis: an underrecognized pattern in systemic sclerosis. Respiration 2009; 77:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wells AU, Hansell DM, Rubens MB, et al. The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. Am Rev Respir Dis 1993; 148:1076.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim EA, Lee KS, Johkoh T, et al. Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. Radiographics 2002; 22 Spec No:S151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177:1248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffmann-Vold AM, Aaløkken TM, Lund MB, et al. Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis. Arthritis Rheumatol 2015; 67:2205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harrison NK, Glanville AR, Strickland B, et al. Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance. Respir Med 1989; 83:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kowal-Bielecka O, Kowal K, Highland KB, Silver RM. Bronchoalveolar lavage fluid in scleroderma interstitial lung disease: technical aspects and clinical correlations: review of the literature. Semin Arthritis Rheum 2010; 40:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wells AU, Hansell DM, Rubens MB, et al. Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance. Am J Respir Crit Care Med 1994; 150:462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goh NS, Veeraraghavan S, Desai SR, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007; 56:2005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strange C, Bolster MB, Roth MD, et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008; 177:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354:2655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujita J, Yoshinouchi T, Ohtsuki Y, et al. Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis 2001; 60:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakamura Y, Chida K, Suda T, et al. Nonspecific interstitial pneumonia in collagen vascular diseases: comparison of the clinical characteristics and prognostic significance with usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tansey D, Wells AU, Colby TV, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004; 44:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicholson AG, Colby TV, Wells AU. Histopathological approach to patterns of interstitial pneumonia in patient with connective tissue disorders. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harrison NK, Myers AR, Corrin B, et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 1991; 144:706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           al-Sabbagh MR, Steen VD, Zee BC, et al. Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study. J Rheumatol 1989; 16:1038.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song JW, Do KH, Kim MY, et al. Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest 2009; 136:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGuire F, Kennelly T, Tillack T, Robbins M. Pulmonary capillary hemangiomatosis associated with CREST syndrome: a case report and review of the literature. Respiration 2010; 80:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Humbert M, Maître S, Capron F, et al. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am J Respir Crit Care Med 1998; 157:1681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Günther S, Jaïs X, Maitre S, et al. Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. Arthritis Rheum 2012; 64:2995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richardson C, Agrawal R, Lee J, et al. Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study. Semin Arthritis Rheum 2016; 46:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kobayashi J, Kitamura S. KL-6: a serum marker for interstitial pneumonia. Chest 1995; 108:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hant FN, Ludwicka-Bradley A, Wang HJ, et al. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol 2009; 36:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takahashi H, Kuroki Y, Tanaka H, et al. Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med 2000; 162:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yanaba K, Hasegawa M, Takehara K, Sato S. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol 2004; 31:1112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kodera M, Hasegawa M, Komura K, et al. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum 2005; 52:2889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gladman DD, Kung TN, Siannis F, et al. HLA markers for susceptibility and expression in scleroderma. J Rheumatol 2005; 32:1481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carmona FD, Martin JE, Beretta L, et al. The systemic lupus erythematosus IRF5 risk haplotype is associated with systemic sclerosis. PLoS One 2013; 8:e54419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peljto AL, Steele MP, Fingerlin TE, et al. The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis. Chest 2012; 142:1584.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4368 Version 29.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24350901" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17330281" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8736656" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14677184" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Scleroderma patients with combined pulmonary hypertension and interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26316389" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22213733" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19541715" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26561397" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Incidence and predictors of interstitial lung disease (ILD) in Thai patients with early systemic sclerosis: Inception cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18403656" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35348643" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31841044" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12718748" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The clinical relevance of autoantibodies in scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12718748" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The clinical relevance of autoantibodies in scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12794797" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3348823" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8214977" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Autoantibody reactive with RNA polymerase III in systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8730118" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: Association with serum anti-U3RNP antibody.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7986226" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Antibodies to histone (H2A-H2B)-DNA complexes in the absence of antibodies to double-stranded DNA or to (H2A-H2B) complexes are more sensitive and specific for scleroderma-related disorders than for lupus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9743170" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16084222" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Autoantibodies in systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19565553" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16874782" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30275265" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9214422" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12070056" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19208563" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18641099" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18799868" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Centrilobular fibrosis: an underrecognized pattern in systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8214928" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12376608" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18369202" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Interstitial lung disease in systemic sclerosis: a simple staging system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25916462" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2694236" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19152959" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Bronchoalveolar lavage fluid in scleroderma interstitial lung disease: technical aspects and clinical correlations: review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8049830" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17530640" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17901414" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16790698" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Cyclophosphamide versus placebo in scleroderma lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11171693" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14620168" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Nonspecific interstitial pneumonia in collagen vascular diseases: comparison of the clinical characteristics and prognostic significance with usual interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15186274" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12002379" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Histopathological approach to patterns of interstitial pneumonia in patient with connective tissue disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1892314" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Structural features of interstitial lung disease in systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2585400" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19255290" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20453487" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Pulmonary capillary hemangiomatosis associated with CREST syndrome: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9603154" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22549387" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27033049" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7634858" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : KL-6: a serum marker for interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19286849" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10903251" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15170923" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16142750" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16078323" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : HLA markers for susceptibility and expression in scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23372721" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The systemic lupus erythematosus IRF5 risk haplotype is associated with systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22576636" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
